Sentences with phrase «diabetes therapy development»
Now, scientists reporting April 12 in Cell Metabolism have discovered a protein that activates the maturation process in vitro, overcoming this longstanding obstacle in diabetes therapy development.
https://www.sciencedaily.com/ Not exact matches
Further studies into this relationship could lead to the development of therapies that treat disorders such as obesity and diabetes.
In addition, the development of therapies that could potentially halt patients» progression from pancreatic inflammation to diabetes has been hampered by the long lead times needed in order to tell whether a given therapy has an effect.
She continued: «Therefore, in further studies, we should investigate how and at what point DPP4 inhibitors can be used in diabetes therapy to prevent the development of non-alcoholic fatty liver disease.»
Antigen - specific therapy using insulin before the development of autoantibodies may induce protective immune responses that prevent the emergence of autoimmunity and subsequent type 1 diabetes in genetically at - risk children, according to background information in the article.
The discovery provides an opportunity to pursue the development of novel drug therapies to address obesity, type 2 diabetes and related metabolic diseases.
«This would aid the development of the next generation of treatments as well as combination therapies for Type 2 diabetes.»
Raydiance's technology has attracted the attention of the U.S. Food and Drug Administration (FDA), which in July 2007 signed the company to a two - year cooperative research and development agreement that has allowed the FDA's Center for Devices and Radiological Health (CDRH) to evaluate the use, safety and effectiveness of Raydiance's USP laser system in a number of areas, including the ablation of corneal tissues in refractive surgery and corneal repair; the administration of light therapy for treating cancer, cardiovascular disease and diabetes; and the removal of plaque on teeth without damaging the enamel.
Solt notes that the study strongly suggests that Th17 cells have a pathological role in the development of type 1 diabetes and use of ROR - specific synthetic compounds targeting this cell type may have potential as a preventative therapy for type 1 diabetes.
Zucara Therapeutics, a spin - off company by The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing the first drug therapy to prevent hypoglycemia in people with diabetes.
The PEC - Encap ™ (also known as VC - 01) product candidate is designed to deliver the same pancreatic progenitor cells in an immunoprotective device and is currently in active development as a therapy for all patients with type 1 diabetes as well as insulin requiring patients with type 2 disease.
ViaCyte's PEC - EncapTM (also known as VC - 01TM) product candidate is the first pluripotent stem cell - derived islet cell replacement therapy for the treatment of type 1 diabetes in clinical - stage development.
SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.
Michigan Medicine and MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN), have entered into a three - year research alliance to identify potential new therapies for the prevention and treatment of diabetes, obesity and related metabolic disorders.
Our research goal is to understand the molecular and cellular events required for pancreatic β - cell regeneration, and apply this knowledge towards the development of cell replacement therapies for diabetes.
The patented discovery comes from Novocell's recognized research & development programs to commercialize pluripotent stem cells for broad research and therapeutic uses, in particular, for an innovative cell therapy for the treatment of diabetes.
World Advanced Therapies and Regenerative Medicine Congress Speaker: Mark Zimmerman, Ph.D., Vice President, Operations and Business Development Presentation: New data on a novel stem cell combination product for diabetes — development and clinical update Date / Time: May 17, 3:30 PM BST Location: Business Design CenDevelopment Presentation: New data on a novel stem cell combination product for diabetes — development and clinical update Date / Time: May 17, 3:30 PM BST Location: Business Design Cendevelopment and clinical update Date / Time: May 17, 3:30 PM BST Location: Business Design Centre, London
JDRF and ViaCyte Announce Support for Development of PEC - Direct Cell Replacement Therapy for Type 1 Diabetes
SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.
In addition, we use our expertise to facilitate the development of functionally mature beta cells from embryonic stem cells for cell replacement therapies of type 1 diabetes.
In addition, the funding will be used to support other operations including the continued development of the PEC - Encap ™ product candidate, ViaCyte's stem cell - derived islet replacement therapy that is being developed as a treatment for all diabetes patients who require insulin to control their disease.
While PEC - Direct development could advance more rapidly and make a major impact for the subset of type 1 diabetes patients at highest risk, we view PEC - EnCap as holding the promise of a functional cure for all patients with type 1 diabetes as well as an important therapy for many patients with type 2 diabetes.»
«We are pleased to have him join to lead ViaCyte through our next phase of development in bringing our transformative stem cell therapy to patients with diabetes.
SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.
Partial clinical hold on high dose SGT - 001 resolved, additional information requested on full clinical hold NIH grant will further development of replacement beta cells for type 1 and type 2 diabetes New trial will assess MSCs to improve heart function in heart failure patients ReNeuron wins grant for retinal cell therapy development
The successful development of a stem cell therapy to alleviate the suffering of millions of Americans afflicted with diabetes is our passion.
«It has been rewarding to be a part of a company that has pioneered the development of stem cell therapy, including the development of technologies that hold promise for the treatment of diabetes,» said Lewis.
Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapies for Type 1 Diabetes
San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.
SAN DIEGO, June 22, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced two presentations at ISSCR 2016 Annual Meeting.
«Novocell is a leader in differentiation of stem cells to create functional islet cells of the pancreas, and this broad patent significantly enhances our proprietary position and further secures our investment in the development of a diabetes cell therapy and potentially other endoderm - derived cell products,» said Edward Baetge, Ph.D., Senior Vice President and Chief Scientific Officer of Novocell.
Although prospective randomized long — term clinical studies comparing the effects of conventional and intensive therapy have demonstrated a clear link between diabetic hyperglycemia and the development of secondary complications of diabetes, they have not defined the mechanism through which excess glucose results in tissue damage.
Notably, the Diabetes Group Therapy Project intervention also includes elements of the four positive development intervention research frameworks.